Sagimet Biosciences (NASDAQ:SGMT) Stock Price Crosses Below 50-Day Moving Average - Here's Why

Sagimet Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Sagimet shares fell below their 50-day moving average of $9.80, trading as low as $9.58 and last quoted at $9.62.
  • Analyst sentiment remains broadly positive: nine analysts rate the stock Buy and two Sell, giving it a consensus “Moderate Buy” rating and an average price target of $26.07.
  • The company reported a quarterly loss of $0.31 per share, missing analyst expectations for a $0.26 loss per share.
  • MarketBeat previews the top five stocks to own by December 1st.

Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report)'s share price crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $9.80 and traded as low as $9.58. Sagimet Biosciences shares last traded at $9.62, with a volume of 1,026,665 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Sagimet Biosciences in a report on Thursday, October 1st. Wells Fargo & Company set a $27.00 price objective on Sagimet Biosciences in a research report on Friday, November 13th. HC Wainwright reissued a "buy" rating and set a $29.00 target price on shares of Sagimet Biosciences in a research note on Monday, October 5th. Guggenheim lifted their target price on Sagimet Biosciences from $25.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, October 2nd. Finally, Wall Street Zen downgraded Sagimet Biosciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Nine equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Sagimet Biosciences has a consensus rating of "Moderate Buy" and an average price target of $26.07.

Get Our Latest Stock Analysis on Sagimet Biosciences

Sagimet Biosciences Price Performance

The company has a market cap of $597.98 million, a PE ratio of -8.08 and a beta of 3.43. The company's 50 day simple moving average is $9.80 and its two-hundred day simple moving average is $7.77.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.05). Sell-side analysts expect that Sagimet Biosciences Inc. will post -1.26 EPS for the current fiscal year.

Institutional Trading of Sagimet Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. RA Capital Management L.P. acquired a new position in Sagimet Biosciences during the third quarter worth $17,784,000. Marshall Wace LLP purchased a new stake in shares of Sagimet Biosciences in the 3rd quarter valued at $7,433,000. Renaissance Technologies LLC raised its holdings in shares of Sagimet Biosciences by 82.6% in the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company's stock valued at $3,268,000 after buying an additional 282,969 shares during the period. Nantahala Capital Management LLC purchased a new stake in shares of Sagimet Biosciences in the 3rd quarter valued at $4,662,000. Finally, Seven Fleet Capital Management LP acquired a new position in Sagimet Biosciences during the 2nd quarter worth about $3,119,000. Hedge funds and other institutional investors own 87.86% of the company's stock.

Sagimet Biosciences Company Profile

(Get Free Report)

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing medicines that target fatty acid synthase (FASN), an enzyme involved in the body's production of fatty acids. The company is based in San Mateo, California. Its lead drug candidate, denifanstat (also known as TVB-2640), is an oral FASN inhibitor being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. The candidate has also been studied for other conditions. Sagimet is also developing TVB-3567, another FASN inhibitor being investigated as a potential treatment for acne.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Sagimet Biosciences Right Now?

Before you consider Sagimet Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sagimet Biosciences wasn't on the list.

While Sagimet Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines